AstraZeneca PLC
GBFinancials
Valuation Metrics
AstraZeneca PLC's Market Cap is $289.48B. At end of 2025 it was $141.02B. Ranked #50 of 3,116 in US market (top 2%), #29 of 1,644 on NYSE (top 2%), #6 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 2%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $289.48B | US#50/3,116 Sec#6/265 |
| Revenue | $61.37B | US#102/3,116 Sec#6/265 |
| Net Income | $10.45B | US#62/3,116 Sec#5/265 |
| Total Assets | $115.70B | US#155/3,116 Sec#8/265 |
| Net Assets | $50.24B | US#87/3,116 Sec#4/265 |
| Employees | 96,100 | US#119/3,116 Sec#2/265 |
| Value | ||
| P/E | 27.71x | US#1,409/3,116 Sec#39/265 |
| P/B | 5.76x | US#2,261/3,116 Sec#147/265 |
| PEG | 1.07x | US#823/3,116 Sec#24/265 |
| P/S | 4.72x | US#2,168/3,116 Sec#73/265 |
| EV/EBITDA | 15.32x | US#1,425/3,116 Sec#38/265 |
| FCF Yield | 3.02% | US#1,753/3,116 Sec#53/265 |
| Profitability | ||
| ROE | 20.79% | US#538/3,116 Sec#27/265 |
| ROA | 9.03% | US#545/3,116 Sec#38/265 |
| Op. Margin | 22.77% | US#764/3,116 Sec#38/265 |
| Revenue Growth | 8.61% | US#1,378/3,116 Sec#103/265 |
| Earnings Growth | 25.93% | US#744/3,116 Sec#27/265 |
| Financial Health | ||
| Debt Ratio | 130.16% | US#1,344/3,116 Sec#175/265 |
| Total Debt | $32.20B | US#149/3,116 Sec#9/265 |
| FCF | $8.74B | US#97/3,116 Sec#12/265 |
| Cash | $4.89B | US#203/3,116 Sec#12/265 |
| Current Ratio | 0.89x | US#2,398/3,116 Sec#257/265 |
| Net Debt/EBITDA | 1.32x | US#1,097/3,116 Sec#49/265 |
| Dividend | ||
| Div. Yield | 1.70% | US#1,004/3,116 Sec#19/265 |
| Div. Growth | 9.78% | US#529/3,116 Sec#6/265 |
| Performance | ||
| 1Y Return | 14.45% | US#1,592/3,116 Sec#135/265 |
| 1M Return | 18.97% | US#1,111/3,116 Sec#70/265 |
| From 52W High | -11.33% | US#1,369/3,116 Sec#74/265 |
| 1Y MDD | -25.41% | US#975/3,116 Sec#41/265 |
| Trading | ||
| Volume | 2,250,100 shares | US#878/3,116 Sec#82/265 |
| Trading Value | $419M | US#297/3,116 Sec#15/265 |
| Per Share | ||
| EPS | $6.74 | US#492/3,116 Sec#13/265 |
| BPS | $32.39 | US#822/3,116 Sec#17/265 |
Company Info
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.